Shan Dong Kexing Bioproducts Co.Ltd(688136) on February 20, it was announced that Shenzhen Kexing Pharmaceutical Co., Ltd. (hereinafter referred to as “Shenzhen Kexing”), a wholly-owned subsidiary, signed the shen26 project cooperation agreement with Shenzhen Aetna Weisheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Aetna Weiwei”) on February 18. SHEN26 is an antiviral drug used to treat COVID-19 and other viral infections. It is a New Coronavirus polymerase (RdRp) inhibitor that can inhibit viral nucleic acid synthesis and achieve antiviral effect.
According to the agreement, Aetna will authorize Shenzhen Kexing to obtain or hold the exclusive rights and interests of shen26’s patents, product development and commercialization in the global region, including the right to use existing and future related patents, product research, registration, clinical and commercial production, distribution and promotion. The project cooperation expenses include the down payment and R & D milestone payment, totaling RMB 100 million, of which the down payment is used to start the project and obtain 10% equity of antaiwei.
The announcement shows that the project has completed laboratory development, is carrying out preclinical pharmacy and process development, and has submitted relevant patent applications. The SHEN26 project has also been included in the 2021 annual New Coronavirus prevention and control New Coronavirus infection science and technology emergency response special project. It is a special key project of the national science and Technology Department’s public safety risk prevention and control and emergency technology and equipment. (Tan pengpeng)
